EVENTS DURING THE THIRD QUARTER
- First patient dosed in the amended HO172 clinical study of tasquinimod in myelofibrosis (July 24)
- Active Biotech expanded US collaboration to advance tasquinimod clinical development in myelofibrosis (August 18)
- Active Biotech announced that global patent protection for laquinimod has been strengthened with Patent Grant in Japan (September 30)
EVENTS AFTER THE END OF THE PERIOD
- First cohort under amended protocol successfully completed safety evaluation in HOVON 172 MF clinical study of tasquinimod in myelofibrosis (October 13)
FINANCIAL SUMMARY
| SEK M | Jul-Sep | Jan-Sep | Full year | ||
| 2026 2025 | 2026 2025 | 2025 | |||
| Net sales | - | - | - | - | - |
| Operating profit/loss | -8,5 | -6.0 | -27.3 | -28.5 | -37.6 |
| Profit/loss after tax | -8,3 | -6.0 | -26.8 | -28.2 | -37.3 |
| Earnings per share (SEK) | -0,32 | -0.49 | -1,02 | -2.29 | -2.77 |
| Cash and cash equivalents (at close of period) | 36.3 | 9.1 | 65.1 | ||
The report is also available at www.activebiotech.com
The information was submitted, through the agency of the contact person below, for public disclosure on 2026-11-05 at 08:30 CEST.
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies have been initiated. Laquinimod is in development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation has been performed to support phase II development together with a partner. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.
